Where Will Eli Lilly Be in 3 Years?

Even with the pullback it has experienced this year, Eli Lilly (NYSE: LLY) has crushed the market over the past three years. The company's shares have more than doubled over this period, making it one of the better-performing pharmaceutical giants.Lilly has several catalysts ahead that could jolt its stock price. But bears might also point to some issues, including increased competition in its core therapeutic areas and rich valuation metrics. How might Eli Lilly perform in the next three years? Let's find out.Eli Lilly's second-quarter revenue jumped by an impressive 38% year over year to $15.6 billion. The drugmaker's best-selling medicines, Mounjaro for diabetes and Zepbound for obesity, are doing much of the heavy lifting. They combined for $8.6 billion in revenue for the period, which was more than half of the company's total top line.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool